Compliance Question of the Week – Pharmacy

Do erythropoiesis-stimulating agents (ESAs) qualify as highly complex drugs?

Can we report 96413, 96415, or 96417 for protectant drugs or rescue therapies?

Can we bill for a sequential infusion in addition to 96413 when a single bag contains multiple drugs or substances?

What system are drugs furnished to hospital outpatients paid under?

What drugs are commonly administered by prolonged intravenous infusion?

Are routine fluids administered over the course of chemotherapy to maintain line patency prior to drugs separately reportable as hydration therapy?

Do we need to bill for monitoring services when further monitoring is required during drug administration?

In a follow-up to last week’s question do any exceptions exist for billing complex drugs for chemotherapy administration?

Do you have any tips on how to bill complex drugs for chemotherapy administration?

How do we bill for drug administration when nursing documentation for intravenous infusion does not note the stop time?

What are the keys to differentiating hydration therapy from drug administration?

We are administering Kytril by injecting it into the bag of hydrating fluid, what codes would we use to bill?